InsideArbitrage Event Driven Monitor – January 9, 2024

The latest twist in the saga is JetBlue’s CEO resignation. I don’t think it means much to the merger but certainly odd timing.

The fact that it is not an immediate departure and the person replacing him is an internal candidate could imply it truly is for health reasons.

Merger Arbitrage

1. AXNX: The acquisition of Axonics (AXNX) by Boston Scientific (BSX) for $3.17 billion or $71 per share in cash.
2. AMAM: The acquisition of Ambrx Biopharma (AMAM) by Johnson & Johnson (JNJ) for $1.33 billion or $28.00 per share in cash.
3. HARP: The acquisition of Harpoon Therapeutics (HARP) by Merck & Co. (MRK) for $371.40 million or $23.00 per share in cash.

Only plus or premium subscribers can access this post. Subscribe today.